These 4 Dividend Stocks Are About to Go Ex-Dividend. Don't Miss the Dates

Four stocks go ex-dividend October 23 or 26, 2026, with payments scheduled in November; buyers must own shares before the ex-date to qualify. Concentrix yields about 4.9% with its $1.48 annualized dividend covered by forecast adjusted free cash flow of $630M–$650M, while Paychex’s roughly 4.2% yield uses 86% of fiscal 2026 EPS. Value Line’s payout ratio is about 66%, and FVCBankcorp’s is about 20%; risks highlighted include Concentrix’s falling revenue, Value Line’s earnings decline, Paychex’s thin coverage, and FVCBankcorp’s commercial-real-estate concentration.

Analysis

Dividend eligibility is a calendar mechanic, not an investment catalyst: the ex-date price adjustment generally offsets the cash payment, so buying today solely to capture CNXC’s dividend—or Friday for the other names—offers no reliable excess return. The more useful signal is the divergence between payout coverage and the businesses’ underlying risk.

CNXC’s adjusted cash-flow cushion does not resolve the more important question: whether revenue can return to growth as clients scrutinize outsourced-service spending and automation changes the economics of contact-center labor. AI adoption could pressure labor-based providers while also creating an opportunity for vendors that can sell higher-value automation services; verify organic revenue, bookings and cash conversion before treating the yield as compensation for the drawdown. A missed stabilization signal over the next 1–3 months would keep the dividend from being a credible floor.

PAYX has the least room to absorb an earnings setback. If growth undershoots management’s fiscal 2027 objective, the likely first-order consequence is slower dividend growth, with a broader valuation reset possible if investors stop treating the payout as dependable. FVCB’s low payout is not a hedge against credit concentration: CRE losses or weaker Washington-area activity could impair capital and earnings well before the dividend ratio looks alarming. VALU’s reported earnings may be less informative than the durability of income outside publishing; confirm its source and cash realization before assigning the payout a premium for longevity.

Near term, expect any dividend-related price adjustment to dominate. Over 1–3 months, watch CNXC organic revenue and FVCB credit quality; over 6–18 months, automation economics and CRE refinancing are the larger structural risks. The contrarian point: apparent dividend safety is not equivalent to total-return safety, especially where earnings quality or revenue direction is deteriorating.

Key Decisions for Investors

• Do not buy any of the four solely to capture the declared payment; the ex-dividend adjustment makes dividend capture an unattractive standalone trade.
• CNXC: keep on a watchlist rather than adding for yield. Reassess after evidence of organic revenue stabilization and cash conversion; continued revenue deterioration would falsify the recovery case even if adjusted dividend coverage remains ample.
• PAYX: avoid treating the current payout as a low-risk bond substitute. Monitor fiscal 2027 adjusted EPS delivery and dividend policy; a guidance reduction or weaker earnings trajectory would strengthen the downside case.
• FVCB: size any exposure around credit risk, not payout ratio. Track CRE delinquencies, criticized assets, loan maturities/refinancing and Washington-area employment; worsening credit metrics would invalidate the benign dividend thesis.
• VALU: before relying on its payout history, verify the source, recurrence and cash realization of earnings outside publishing. If those earnings prove volatile, the headline EPS payout ratio may understate dividend risk.